Open main menu

List of investigational antidepressants

This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. All drugs listed are specifically under development for major depressive disorder (MDD) or treatment-resistant depression (TRD) unless noted otherwise.

GlutamatergicsEdit

NMDA receptor modulatorsEdit

OthersEdit

MonoaminergicsEdit

Monoamine reuptake inhibitorsEdit

Monoamine reuptake inhibitors and receptor modulatorsEdit

Monoamine receptor modulatorsEdit

Atypical antipsychoticsEdit

  • Brilaroxazine (RP-5063, RP-5000) – AA – specifically under development for the treatment of MDD and depressive episodes in bipolar disorder[23]
  • Lumateperone (ITI-007) – AA – specifically under development for the treatment of depressive episodes in bipolar disorder[24]

OthersEdit

NeurosteroidsEdit

GABAA receptor positive modulatorsEdit

  • Ganaxolone (CCD-1042) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of postpartum depression[26]
  • Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of both MDD and postpartum depression[27]

OthersEdit

OpioidergicsEdit

κ-Opioid receptor antagonistsEdit

OthersEdit

OthersEdit

MixedEdit

CombinationsEdit

Not under developmentEdit

The following drugs are currently of investigational interest as potential antidepressants but are not formally under clinical development for approval at this time:

See alsoEdit

ReferencesEdit

  1. ^ "AV 101". adisinsight.springer.com. Retrieved 7 May 2017.
  2. ^ "AGN-241751 - Allergan". adisinsight.springer.com. Retrieved 28 August 2018.
  3. ^ "Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". www.prnewswire.com. Retrieved 28 August 2018.
  4. ^ "Apimostinel". adisinsight.springer.com. Retrieved 7 May 2017.
  5. ^ a b Hashimoto, Kenji (2019). "Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective". Psychiatry and Clinical Neurosciences. 73 (10): 613–627. doi:10.1111/pcn.12902. ISSN 1323-1316.
  6. ^ https://adisinsight.springer.com/drugs/800056158
  7. ^ "Dextromethadone - Relmada Therapeutics". adisinsight.springer.com. Retrieved 10 November 2018.
  8. ^ "EVT 101". adisinsight.springer.com. Retrieved 7 May 2017.
  9. ^ "Ketamine intranasal - Vyera Pharmaceuticals". adisinsight.springer.com. Retrieved 7 May 2017.
  10. ^ "CERC 301". adisinsight.springer.com. Retrieved 7 May 2017.
  11. ^ "Basimglurant". adisinsight.springer.com. Retrieved 7 May 2017.
  12. ^ Machado-Vieira R, Henter ID, Zarate CA (May 2017). "New targets for rapid antidepressant action". Progress in Neurobiology. 152: 21–37. doi:10.1016/j.pneurobio.2015.12.001. PMC 4919246. PMID 26724279.
  13. ^ a b Lener MS, Kadriu B, Zarate CA (March 2017). "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression". Drugs. 77 (4): 381–401. doi:10.1007/s40265-017-0702-8. PMC 5342919. PMID 28194724.
  14. ^ "Tulrampator". adisinsight.springer.com. Retrieved 31 May 2017.
  15. ^ "AN 788". adisinsight.springer.com. Retrieved 7 May 2017.
  16. ^ "LY 03005". adisinsight.springer.com. Retrieved 7 May 2017.
  17. ^ "PDC-1421". adisinsight.springer.com. Retrieved 24 March 2018.
  18. ^ "MIN 117". adisinsight.springer.com. Retrieved 7 May 2017.
  19. ^ "FKB 01MD". adisinsight.springer.com. Retrieved 7 May 2017.
  20. ^ "Gepirone ER". adisinsight.springer.com. Retrieved 7 May 2017.
  21. ^ "Pimavanserin". adisinsight.springer.com. Retrieved 25 September 2017.
  22. ^ "Psilocybin". adisinsight.springer.com. Retrieved 26 October 2018.
  23. ^ "RP 5063". adisinsight.springer.com. Retrieved 7 May 2017.
  24. ^ "Lumateperone". adisinsight.springer.com. Retrieved 7 May 2017.
  25. ^ "Ademetionine". adisinsight.springer.com. Retrieved 7 May 2017.
  26. ^ "Ganaxolone". adisinsight.springer.com. Retrieved 24 March 2018.
  27. ^ "SAGE 217". adisinsight.springer.com. Retrieved 9 February 2018.
  28. ^ "Pregnenolone methyl ether". adisinsight.springer.com. Retrieved 7 May 2017.
  29. ^ "PH 10 nasal spray". adisinsight.springer.com. Retrieved 7 May 2017.
  30. ^ "Aticaprant". adisinsight.springer.com. Retrieved 11 November 2019.
  31. ^ "Buprenorphine/samidorphan". adisinsight.springer.com. Retrieved 7 May 2017.
  32. ^ "BTRX-246040". adisinsight.springer.com. Retrieved 24 March 2018.
  33. ^ Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. (May 2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533 (7604): 481–6. doi:10.1038/nature17998. PMC 4922311. PMID 27144355. Lay summaryScienceDaily.
  34. ^ "JNJ 39393406". adisinsight.springer.com. Retrieved 7 May 2017.
  35. ^ "JNJ-54175446". adisinsight.springer.com. Retrieved 24 March 2018.
  36. ^ "Research programme: psychiatric and neurological disorders therapeutics - Neuronascent". adisinsight.springer.com. Retrieved 7 May 2017.
  37. ^ "NSI 189". adisinsight.springer.com. Retrieved 7 May 2017.
  38. ^ "NV 5138". adisinsight.springer.com. Retrieved 7 November 2018.
  39. ^ Duman RS (2018). "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide". F1000Research. 7: 659. doi:10.12688/f1000research.14344.1. PMC 5968361. PMID 29899972.
  40. ^ Duman R, Kato T, Liu RJ, Duman C, Terwilliger R, Vlasuk G, Hahm S, Sajah E (November 2017). "Sestrin 2 Modulator NV-5138 Shows Ketamine-Like Rapid Antidepressant Effects via Direct Activation of mTORC1 Signaling" (PDF). Neuropsychopharmacology. 43: S195.
  41. ^ "Botulinum toxin A injectable - Allergan". adisinsight.springer.com. Retrieved 7 May 2017.
  42. ^ "JNJ 42847922". adisinsight.springer.com. Retrieved 7 May 2017.
  43. ^ "Sirukumab". adisinsight.springer.com. Retrieved 7 May 2017.
  44. ^ "SUVN-911". adisinsight.springer.com. Retrieved 24 March 2018.
  45. ^ "TS 121". adisinsight.springer.com. Retrieved 7 May 2017.
  46. ^ "Tramadol controlled release - e-Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
  47. ^ "Another depression drug flops as e-Therapeutics tallies PhIIb data - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018.
  48. ^ "E-Therapeutics defends PhIIb fail, claiming drug has 'pretty much' the hoped-for profile - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018.
  49. ^ "Bupropion/dextromethorphan - Axsome Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
  50. ^ "Cycloserine/lurasidone - NeuroRx". adisinsight.springer.com. Retrieved 7 May 2017.
  51. ^ "Deudextromethorphan". adisinsight.springer.com. Retrieved 7 May 2017.
  52. ^ Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM (November 2013). "Small molecules activating TrkB receptor for treating a variety of CNS disorders". CNS & Neurological Disorders Drug Targets. 12 (7): 1066–77. doi:10.2174/18715273113129990089. PMID 23844685.
  53. ^ Zhang JC, Yao W, Hashimoto K (2016). "Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets". Current Neuropharmacology. 14 (7): 721–31. doi:10.2174/1570159X14666160119094646. PMC 5050398. PMID 26786147.
  54. ^ Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5: 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.
  55. ^ Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". Journal of Medicinal Chemistry. 53 (23): 8274–86. doi:10.1021/jm101206p. PMC 3150605. PMID 21073191.
  56. ^ Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (October 2014). "Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation". The International Journal of Neuropsychopharmacology. 18 (4). doi:10.1093/ijnp/pyu077. PMC 4360225. PMID 25628381.
  57. ^ Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (December 2015). "Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression". Psychopharmacology. 232 (23): 4325–35. doi:10.1007/s00213-015-4062-3. PMID 26337614.
  58. ^ Chang HA, Wang YH, Tung CS, Yeh CB, Liu YP (September 2016). "7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress". Psychiatry Investigation. 13 (5): 531–540. doi:10.4306/pi.2016.13.5.531. PMC 5067348. PMID 27757132.
  59. ^ Zhang MW, Zhang SF, Li ZH, Han F (December 2016). "7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress". Neuroscience Letters. 635: 33–38. doi:10.1016/j.neulet.2016.10.035. PMID 27773794.
  60. ^ Rosenblat JD, McIntyre RS (February 2018). "Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials". Journal of Affective Disorders. 227: 219–225. doi:10.1016/j.jad.2017.10.042. PMID 29102836.
  61. ^ Cohen IV, Makunts T, Atayee R, Abagyan R (May 2017). "Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications". Scientific Reports. 7 (1): 1450. doi:10.1038/s41598-017-01590-x. PMC 5431207. PMID 28469132.
  62. ^ Nagele P, Zorumski CF, Conway C (April 2018). "Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts". Journal of Clinical Psychopharmacology. 38 (2): 144–148. doi:10.1097/JCP.0000000000000837. PMC 5825282. PMID 29360650.
  63. ^ Zorumski CF, Nagele P, Mennerick S, Conway CR (2015). "Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy". Frontiers in Psychiatry. 6: 172. doi:10.3389/fpsyt.2015.00172. PMC 4673867. PMID 26696909.
  64. ^ Harrison, Pam (April 7, 2016). "Parkinson's Drug Highly Effective for Resistant Depression". www.medscape.com. WebMD. Retrieved 2018-02-12.
  65. ^ Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 115 (3): 578–583. doi:10.1073/pnas.1718683115. PMC 5777001. PMID 29295929.

Further readingEdit

External linksEdit